What should we do about vaccination of patients on anti-CD20 antibody therapy?

Affiliations

Editorial

Takayoshi Shimohata. J Neurol Neurosurg Psychiatry. 2022 Jan.

. 2022 Jan;93(1):4.

doi: 10.1136/jnnp-2021-327371. Epub 2021 Aug 2.

¹ Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan shimohata@gmail.com.

No abstract available

Keywords: COVID-19.

Conflict of interest statement

Competing interests: None declared.

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C, Ibrahim M, Maillart E, Abdi B, Papeix C, Stankoff B, Dubessy AL, Bensa-Koscher C, Créange A, Chamekh Z, Lubetzki C, Marcelin AG, Corvol JC, Pourcher V; COVISEP and Bio-coco-neuroscience study group. Louapre C, et al. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):24-31. doi: 10.1136/jnnp-2021-326904. Epub 2021 Aug 2. J Neurol Neurosurg Psychiatry. 2022. PMID: 34341142 Clinical Trial.